Circulating Levels andex VivoProduction of β-Chemokines, Interferon γ, and Interleukin 2 in Advanced Human Immunodeficiency Virus Type 1 Infection: The Effect of Protease Inhibitor Therapy

2000 ◽  
Vol 16 (9) ◽  
pp. 835-843 ◽  
Author(s):  
Andrea De Luca ◽  
Maria Letizia Giancola ◽  
Antonella Cingolani ◽  
Adriana Ammassari ◽  
Rita Murri ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Interleukin 2 ◽  
Interferon Γ ◽  
Protease Inhibitor Therapy ◽  
Immunodeficiency Virus ◽  
Circulating Levels

scholarly journals Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy

2000 ◽  
Vol 182 (3) ◽  
pp. 758-765 ◽  
Author(s):  
Jon H. Condra ◽  
Christos J. Petropoulos ◽  
Rainer Ziermann ◽  
William A. Schleif ◽  
Malathi Shivaprakash ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Resistance ◽  
Protease Inhibitor ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Inhibitor Therapy ◽  
Protease Inhibitor Therapy ◽  
Immunodeficiency Virus

scholarly journals TMC310911, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, ShowsIn Vitroan Improved Resistance Profile and Higher Genetic Barrier to Resistance Compared with Current Protease Inhibitors

2011 ◽  
Vol 55 (12) ◽  
pp. 5723-5731 ◽  
Author(s):  
Inge Dierynck ◽  
Herwig Van Marck ◽  
Marcia Van Ginderen ◽  
Tim H. M. Jonckers ◽  
Madhavi N. L. Nalam ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Protease Inhibitor ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Clinical Isolates ◽  
Immunodeficiency Virus ◽  
Hiv 1 ◽  
Selection Of

ABSTRACTTMC310911 is a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) structurally closely related to darunavir (DRV) but with improved virological characteristics. TMC310911 has potent activity against wild-type (WT) HIV-1 (median 50% effective concentration [EC50], 14 nM) and a wide spectrum of recombinant HIV-1 clinical isolates, including multiple-PI-resistant strains with decreased susceptibility to currently approved PIs (fold change [FC] in EC50, >10). For a panel of 2,011 recombinant clinical isolates with decreased susceptibility to at least one of the currently approved PIs, the FC in TMC310911 EC50was ≤4 for 82% of isolates and ≤10 for 96% of isolates. The FC in TMC310911 EC50was ≤4 and ≤10 for 72% and 94% of isolates with decreased susceptibility to DRV, respectively.In vitroresistance selection (IVRS) experiments with WT virus and TMC310911 selected for mutations R41G or R41E, but selection of resistant virus required a longer time than IVRS performed with WT virus and DRV. IVRS performed with r13025, a multiple-PI-resistant recombinant clinical isolate, and TMC310911 selected for mutations L10F, I47V, and L90M (FC in TMC310911 EC50= 16). IVRS performed with r13025 in the presence of DRV required less time and resulted in more PI resistance-associated mutations (V32I, I50V, G73S, L76V, and V82I; FC in DRV EC50= 258). The activity against a comprehensive panel of PI-resistant mutants and the limitedin vitroselection of resistant viruses under drug pressure suggest that TMC310911 represents a potential drug candidate for the management of HIV-1 infection for a broad range of patients, including those with multiple PI resistance.

scholarly journals Results of 2 Years of Treatment with Protease‐Inhibitor–Containing Antiretroviral Therapy in Dutch Children Infected with Human Immunodeficiency Virus Type 1

2002 ◽  
Vol 34 (7) ◽  
pp. 1008-1016 ◽  
Author(s):  
Annemarie M. C. van Rossum ◽  
Sibyl P. M. Geelen ◽  
Nico G. Hartwig ◽  
Tom F. W. Wolfs ◽  
Corry M. R. Weemaes ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiretroviral Therapy ◽  
Protease Inhibitor ◽  
Human Immunodeficiency Virus Type ◽  
Virus Type ◽  
Immunodeficiency Virus ◽  
Dutch Children
Sign in / Sign up

Export Citation Format

Share Document